K-V Pharmaceutical Class A (KVPHQA)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Employees:
16640 CHESTERFIELD GROVE ROAD, SUITE 200, CHESTERFIELD, MO 63005
3146456600

• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

N/A

Data derived from most recent annual or quarterly report
Market Cap 31.542 Million Shares Outstanding60.08 Million Avg 30-day Volume 2.196 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-1.71
Price to Revenue0.0 Debt to Equity-2.8104 EBITDA-30.4 Million
Price to Book Value0.0 Operating Margin-1825.8621 Enterprise Value0
Current Ratio0.606 EPS Growth1.355 Quick Ratio0.655
1 Yr BETA -0.6468 52-week High/Low 0.0 / Profit Margin-1322.8449
Operating Cash Flow Growth-18.4326 Altman Z-Score0.0 Free Cash Flow to Firm -194.94 Million
View SEC Filings from KVPHQA instead.

View recent insider trading info

K-V Pharmaceutical Class A YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding KVPHQA (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding KVPHQA

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

BENTLEY GREGORY SMITH

  • Director
 0 2011-09-08 0

MCHUGH THOMAS S CHIEF FINANCIAL OFFICER

  • Officer
 0 2011-09-08 0

BALDINI ROBERT E

  • Director
 0 2011-09-08 0

LEHRER JOSEPH D

  • Director
 0 2011-09-08 0

SIDRANSKY DAVID

  • Director
 0 2011-09-08 0

HERMELIN DAVID S

  • Director
 0 2011-09-08 0

STANCIC ANA

  • Director
 0 2011-09-08 0

DIVIS GREG J CEO AND PRESIDENT

  • Officer
 0 2011-09-08 0

DOW MARK A.

  • Director
 0 2011-09-08 0

CHRISTMAS PATRICK J. GENERAL COUNSEL

  • Officer
 0 2011-06-01 0

HERMELIN ARNOLD L

  • 10% Owner
 289,179 2011-03-04 0

PARKSIDE FINANCIAL BANK & TRUST

  • 10% Owner
 761,526 2011-02-11 0

U.S. HEALTHCARE I, L.L.C.

CENTERBRIDGE PARTNERS HOLDINGS, LLC

CENTERBRIDGE CREDIT ADVISORS, L.L.C.

CENTERBRIDGE SPECIAL CREDIT ADVISORS, L.L.C.

U.S. HEALTHCARE II, L.L.C.

ARONSON JEFFREY

GALLOGLY MARK T

CENTERBRIDGE PARTNERS, L.P.

  • 10% Owner
 0 2010-11-17 0

HERMELIN MARC S

  • 10% Owner
 0 2010-11-15 0

HARTMAN MARK T. PRES. - GENERICS DIVISION

  • Officer
 0 2010-10-13 0

SAMPSON JOHN R.

  • Director
 7,500 2010-06-10 0

STAMP STEPHEN CFO

  • Officer
 0 2010-04-08 0

FORSYTH JANICE C. VP, GEN. COUNSEL & SECRETARY

  • Officer
 0 2010-01-11 0

VAN VLIET DAVID A INTERIM PRES./ INTERIM CEO, KV

  • Officer
 0 2009-04-24 0

BRADY PAUL T PRESIDENT, PDI

  • Officer
 0 2009-04-24 0

CARLIE KEVIN S

  • Director
 0 2009-01-13 0

SCHELLENGER NORMAN D

  • Director
 0 2009-01-13 0

BELLIN JEAN M

  • Director
 0 2009-01-13 0

HATFIELD TERRY B

  • Director
 0 2009-01-13 0

ANDERSON MICHAEL SHANNON CEO, ETHEX CORPORATION

  • Officer
 0 2009-01-13 0

KANTERMAN RONALD J VP, CFO & TREASURER

  • Officer
  • Director
 0 2009-01-13 0

KILLMER JONATHON E

  • Director
 0 2009-01-13 0

BLESER RITA PRES. - PHARMACEUTICAL DIV.

  • Officer
 0 2009-01-13 0

CHIBNALL RICHARD H VICE PRESIDENT/FINANCE

  • Officer
 4,350 2008-11-13 0

MITCHELL GERALD R VICE PRESIDENT AND CFO

  • Officer
  • Director
 110,115 2008-01-05 0

MOYERMAN ERIC D PRESIDENT, PHARMACEUTICAL DIV.

  • Officer
 11,124 2007-05-15 0

MCCULLOUGH PATRICIA K CEO, ETHEX CORP.

  • Officer
 50,000 2006-03-31 0

JOHNSON ALAN G SR.. VICE PRES. & SEC.

  • Officer
  • Director
 173,686 2006-02-16 0

CHIOSTRI RAYMOND F VP; P - PARTICLE DYNAMICS -SUB

  • Officer
 28,875 2006-01-20 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

No recent transactions

*** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

Elevate your investments